Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.02032
European Journal of Endocrinology, Vol 153, Issue 6, 981-988
Copyright © 2005 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Enjuanes, A.
Right arrow Articles by Díez-Pérez, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Enjuanes, A.
Right arrow Articles by Díez-Pérez, A.

EXPERIMENTAL STUDY

Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation

Anna Enjuanes, Natalia Garcia-Giralt1, August Supervía, Xavier Nogués, Silvia Ruiz-Gaspà, Mariona Bustamante1, Leonardo Mellibovsky, Daniel Grinberg1, Susana Balcells1 and Adolfo Díez-Pérez

URFOA-IMIM, Hospital del Mar, Universitat Autònoma de Barcelona, E-08003 Barcelona, Spain and 1 Department of Genetics, Universitat de Barcelona, Barcelona, Spain

(Correspondence should be addressed to A Enjuanes; Email: aenjuanes{at}clinic.ub.es)

Objective: Current evidence suggests that extragonadal estrogens play an important role in bone metabolism. Estrogen biosynthesis is catalyzed by P450aromatase, encoded by the CYP19 gene. The aims of this paper were to study CYP19 gene expression in human osteoblasts under several hormone and cytokine treatments and to define promoter regions involved in this regulation.

Methods: CYP19 transcript levels were measured from primary human osteoblasts and MG-63 cells by real-time PCR in basal conditions, and in response to seven different hormones and cytokines. Four promoters of CYP19 gene were cloned upstream of the luciferase gene and transfected into MG-63 cells. The effect of vitamin D and dexamethasone in these promoter activities was evaluated.

Results: Vitamin D and dexamethasone were potent stimulators of CYP19 transcription, while testosterone and 17ß-estradiol stimulated moderately. Promoter pII proved the most potent in driving transient luciferase expression. Promoter I.4 displayed moderate activity, while promoters I.3 and I.6 were weak. A region upstream of exon I.3, including exon I.6, was identified as containing repressor elements of promoter pII. Promoter I.3 activity was modulated by repressors located within exon I.3, while an enhancer of promoter I.4 was detected within exon I.4. In the absence of fetal calf serum, dexamethasone stimulation was observed on promoters I.3 and I.4, while vitamin D stimulation acted only on promoter I.3.

Conclusions: Four regulatory regions of promoters pII, I.3 and I.4 are relevant to CYP19 expression in human osteoblasts. Vitamin D and dexamethasone modulate transcription through these regions.




This article has been cited by other articles:


Home page
Arch Intern MedHome page
O. Dizdar, H. Harputluoglu, and K. Altundag
Vitamin D Intake and Breast Cancer Risk in Postmenopausal Women
Arch Intern Med, December 10, 2007; 167(22): 2532 - 2532.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 European Society of Endocrinology.